Invivyd Inc (IVVD)
1.84
+0.03
(+1.66%)
USD |
NASDAQ |
May 31, 16:00
1.83
-0.01
(-0.54%)
After-Hours: 20:00
Invivyd SG&A Expense (Quarterly): 14.93M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 14.93M |
December 31, 2023 | 15.09M |
September 30, 2023 | 12.89M |
June 30, 2023 | 10.11M |
March 31, 2023 | 11.04M |
December 31, 2022 | 10.52M |
September 30, 2022 | 13.20M |
Date | Value |
---|---|
June 30, 2022 | 14.62M |
March 31, 2022 | 8.704M |
December 31, 2021 | 14.66M |
September 30, 2021 | 11.05M |
June 30, 2021 | 7.124M |
March 31, 2021 | 3.677M |
September 30, 2020 | 0.842M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.842M
Minimum
Sep 2020
15.09M
Maximum
Dec 2023
10.60M
Average
11.05M
Median
SG&A Expense (Quarterly) Benchmarks
Vanda Pharmaceuticals Inc | 30.08M |
Viking Therapeutics Inc | 9.97M |
Stoke Therapeutics Inc | 10.22M |
180 Life Sciences Corp | 1.557M |
MAIA Biotechnology Inc | 1.628M |